Full Title
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationPurpose
Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.
INCB161734 targets and blocks the mutated KRAS G12D protein, which is found in cancer cells. By blocking this protein, INCB161734 may slow or stop the growth of your cancer. INCB161734 is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have advanced pancreatic, colorectal, or non-small cell lung cancer with a KRAS G12D mutation.
- Have completed prior anti-cancer therapies at least 4 weeks before taking INCB161734.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Eileen O’Reilly’s office at 646-888-4182.
Protocol
24-292
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06179160